Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | May 24, 2023
Finance
May 23 Quick Takes: VCs back cancer play Larkspur with $35.5M
Plus: PTC reports vatiquinone Phase III miss, discontinuation of gene therapies and updates from Innoviva, Pfizer, Wave, Arrowhead, Icosavax and more
BioCentury | Mar 2, 2023
Data Byte
At least nine PDUFA dates on deck in March
Decisions include leniolisib and trofinetide, both of which could be the first drugs approved for their indications
BioCentury | Aug 23, 2022
Product Development
The new modality pipeline against ANGPTL3 grows with Verve’s new program
At least two gene editing therapies and three RNA therapies against ANGPTL3 set to compete in dyslipidemia indications
BioCentury | Jan 31, 2022
Deals
After review of Phase IIb data, Pfizer hands back CV program to Ionis
The pharma sunk $325M into vupanorsen, but won’t get its ‘mega-blockbuster’ in cardiovascular indications
BioCentury | Dec 23, 2021
Product Development
First-in-class drugs fill FDA’s 2021 class of new approvals
Products against new targets accounted for nearly one third of NMEs, and fewer of them were for cancer than you might think
BioCentury | Nov 25, 2021
Product Development
Nov. 24 Quick Takes: Pfizer’s vupanorsen meets in Phase IIb
Plus Selecta’s clinical hold, Allorion’s fund-raising and a Philogen-Janssen deal
BioCentury | Mar 5, 2021
Translation in Brief
A stem cell therapy for brain metastases in breast cancer; plus a nanoparticle gene editing delivery tech and more
BioCentury’s roundup of translational news
BioCentury | Feb 12, 2021
Regulation
FDA approval of Regeneron’s Evkeeza brings new drug class to HoFH patients
Regeneron’s Evkeeza evinacumab-dgnb gained FDA approval Thursday as the first ANGPTL3 inhibitor to treat homozygous familial hypercholesterolemia, offering a new mechanism
BioCentury | Aug 31, 2020
Deals
Three years after spinout, Ionis brings back Akcea in $500M acquisition
Three years after Ionis spun out its Akcea unit in an IPO, and nearly a year after the parent company installed a new CEO at the subsidiary, Ionis has chosen to retake full ownership of Akcea in a
BioCentury | Aug 13, 2020
Regulation
Aug. 12 Quick Takes: Approvals for DMD, acute pain; plus Priority Review for Fabry, hypercholesterolemia therapies and more
FDA approves a second targeted DMD therapyNS Pharma Inc.’s Viltepso viltolarsen received accelerated approval from FDA to treat Duchenne muscular dystrophy in patients amenable to exon 53
Items per page:
1 - 10 of 33